TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial.

Benjamin Speich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.